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Introduction
The mammalian cell cycle is controlled by cyclin-dependent 
kinases (CDKs) and their related pathways (Fig. 1) [1, 2]. 
The CDKs, particularly CDK1, CDK2, and CDK4/6, are 
activated via binding to their selected cyclins, including 
cyclins A, B, D, and e, in specific phases of the cell cycle, 
following which they phosphorylate their target proteins to 
enable cell cycle progression. The activities of the CDKs 
are controlled not only by cyclins but also by phosphoryla-
tion or dephosphorylation by wee1 kinase or CDC25 phos-
phatase [1]. Moreover, CDK inhibitors including p15ink4b, 
p16 ink4a, p18 ink4d, p21Cip1, p27 Kip1, and p57 Kip2 specifi-
cally bind to their target cyclin–CDK complexes and inhibit 
their activities to negatively regulate the cell cycle [3–5].
CDKs and their related pathways control the cell cycle 
by maintaining exit and entry to the different phases of the 
cell cycle. In the G1 phase, growth stimuli such as growth 
factors often activate the MAP kinase pathway, following 
which genes encoding the cyclin Ds are transcribed. The 
resulting products bind to and activate CDK4/6 [6]. Cyc-
lin Ds–CDK4/6 complexes phosphorylate retinoblastoma 
protein (pRB) and its family members, p107 and p130, in 
the late G1 phase and activate e2F-mediated transcription, 
which induces the expression of several growth-promoting 
genes [7, 8]. At the G1/S transition point, cyclin e-CDK2 
phosphorylates pRB as well as several proteins involved in 
DNA replication to promote G1/S progression [9]. Cyclin 
B-CDK1 has many targets including APC/cyclosome, and 
promotes maturation of the G2 phase and critically partici-
pates in M phase events [10].
The cellular levels of cell cycle regulators such as cyc-
lins, CDKs, CDK inhibitors, CDC25, RB, and e2F are 
critical for cell cycle regulation. After the cell cycle regu-
lators complete their functions, they are ubiquitylated by 
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specific e3 ligases and eliminated via the ubiquitin–pro-
teasome pathway [11–13]. The level of cell cycle regula-
tors is precisely controlled by not only post-translational 
but also translational mechanisms. For example, several 
micro-RNAs (miRNAs) participate in cell cycle regulation 
through translational regulation [14]. MiRNAs are small 
non-coding RNA molecules containing 22 nucleotides, 
and negatively regulate translation through binding of the 
untranslated region of its target mRNAs [15]. The let-7 
miRNA family negatively regulates cyclins A and D, and 
CDK4/6 and CDC25A [16]. The miR-15 family also inhib-
its the translation of cyclin D, CDK4, and CDC27 [17, 18]. 
Interestingly, these let-7 and miR-15 family members may 
be involved in tumorigenesis since they are downregulated 
in various human cancers [16–18]. Alternatively, cyclin 
D1 is a target for not only let-7 and miR-15 miRNAs but 
also miR-19a, 26a, and 34a [15]. Furthermore, p27 Kip1 is 
targeted for regulation by the miR-181 family [19] and the 
miR-221 family [20]. The roles of other miRNAs in the 
expression of cell cycle regulators have also been reported 
[15]. Thus, it has been shown that the cell cycle regulators 
are critically and precisely controlled by e3 ligases and 
miRNAs both post-translationally and at the translational 
level.
Here, we focus on long non-coding RNAs (lncRNAs) 
involved in the regulation of the cell cycle through their 
various functions as epigenetic regulators, transcription 
factor regulators, post-transcription regulators and protein 
scaffolds [21, 22]. LncRNAs are non-protein coding tran-
scripts longer than 200 nucleotides, and can be divided into 
at least five categories based on their structural character-
istics, including intergenic lncRNAs (lincRNAs), intronic 
lncRNAs, natural antisense transcripts, pseudogenes, and 
retrotransposons [23]. Recent mass-scale transcriptome 
analysis has revealed that many kinds of lncRNAs are tran-
scribed in large amounts in the eukaryotic genome [24]. 
However, the question remains as to whether these lncR-
NAs are merely by-products of the transcriptional units or 
have a critical function for biological processes. However, 
it has become clear that some of these lncRNAs participate 
in various biological processes such as genome imprinting, 
X-inactivation, development, differentiation, and cell cycle 
regulation [22, 24–26]. For example, HOTAIR, a well-













Fig. 1  Outline of cell cycle control and involvement of lncRNAs. 
The mammalian cell cycle is controlled by cyclin-dependent kinases 
(CDKs) and their related pathways. CDKs are activated via binding 
to their selected cyclins in specific phases of the cell cycle, follow-
ing which they phosphorylate their target proteins. The CDK inhibi-
tors (CKIs) negatively regulate the activities of CDKs and control the 
cell cycle. pRB regulates G1/S progression. The p53 pathway plays a 
role in DNA damage response as a gatekeeper of the genome. Several 
lncRNAs control the expression of cyclins-CDKs, CKIs, pRB and 
p53, and participate in cell cycle regulation. Some of these lncRNAs 
are induced by DNA damage and inhibit cell cycle progression by 
regulating these cell cycle regulators
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and tumorigenesis through recruiting the polycomb group 
(PcG) complex to its targeted HOX genes for their repres-
sion [26, 27]. The PcG complex contributes to the epige-
netic regulation of its target genes by forming Polycomb 
repressive complex 1 (PRC1) and 2 (PRC2). PRC2 partici-
pates in histone H3K27 methylation and, following histone 
H2AK119 monoubiquitination by PRC1, collaboratively 
represses target gene transcription. In addition to HOTAIR, 
several lncRNAs such as XIST, AIR, and KCNQ1OT1 
also recruit chromatin modifiers including PcG and H3K9 
methyltransferase G9a to their target loci [25, 28–30]. 
Moreover, ANRIL (antisense non-coding RNA in the INK4 
locus) directly binds to PcGs and recruits them to the INK4 
locus to promote gene silencing [31, 32]. Thus, HOTAIR, 
XIST, AIR, KCNQ1OT1, and ANRIL function as epigenetic 
regulators by negatively regulating target gene transcription 
through recruitment of chromatin modifiers. Recently, sev-
eral lncRNAs that participate in the expression of several 
cell cycle regulators have been reported (summarized in 
Fig. 1; Table 1). In this review, we introduce these lncR-
NAs and discuss their functions in cell cycle regulation. 
LncRNAs regulating cyclins and CDKs
Cyclins and CDKs are key players in cell cycle regulation 
(Fig. 1). NcRNACCND1, also called pncRNA (promoter-asso-
ciated non-coding RNA), is transcribed from the upstream 
region of the cyclin D1 gene, CCND1, and negatively 
regulates cyclin D1. NcRNACCND1 functions as a transcrip-
tion factor regulator [33]. It is induced in a DNA damage-
dependent manner, and associates with and recruits TLS 
(translocated in liposarcoma) [34], an RNA binding pro-
tein. The ncRNACCND1-TLS complex is recruited to the 
CCND1 promoter to inhibit the activity of the coactiva-
tor, CBP/p300, thereby preventing CCND1 transcription 
(Fig. 2a). Thus, suppression of cyclin D1 regulated by the 
ncRNACCND1-TLS complex may participate in G1 arrest in 
response to DNA damage.
Gadd7 is an lncRNA involved in regulating CDK6 
expression [35] in a posttranscriptional manner. TDP-43 
(TAR DNA binding protein) binds to the 3′ untranslated 
region of CDK6 mRNA to stabilize it. Gadd7 is transcrip-
tionally induced via DNA damage mediated by Uv and cis-
platin [35, 36], and binds to TDP-43 and dissociates from 
CDK6 mRNA. The CDK6 mRNA is then degraded, result-
ing in inhibition of the G1/S transition (Fig. 2b). Therefore, 
gadd7 negatively controls CDK6 expression, functioning 
as a translation regulator. Interestingly, gadd7 specifically 
controls mRNA stability for CDK6, but not CDK4, CDK2, 
or CCND1, by trapping TDP-43. The physiological rel-
evance of the selective suppression of CDK6 remains to be 
determined. Gadd7 may be involved in the G1 checkpoint 
by collaborating with the lncRNA, ncRNACCND1, to down-
regulate the cyclin D1–CDK6 complex, thereby arresting 
cell cycle progression in response to DNA damage (Fig. 2a, 
b). This may represent a novel G1-checkpoint cascade, but 
further studies are required.
MALAT1, an mRNA splicing mediator [37], is upregu-
lated in several human cancers and contributes to cancer 
cell proliferation [38]. MALAT1 depletion results in arrest 
at G1 and promotes expression of p53 as well as p16, p21, 
and p27 in human fibroblasts [39] (Table 1). In contrast, 
MALAT1 depletion suppresses various genes involved in 
Table 1  LncRNAs involved in the cell cycle control
lncRNA How it is induced The effects of the lncRNA on its targets in cell cycle (phase) References
ncRNACCNDI DNA damage Suppression of Cyclin D1 transcription with TLS (G1) [33, 34]
gadd7 DNA damage Destabilization of CDK6 mRNA (G1) [35, 36]
MALAT1 High expression In cancer Promotion of cell-cycle regulators such as cyclin A2 and B1 (G1 and G2/M) [37–39]
SRA ? Suppression of Cyclin A, B cdc20. Cdt1 transcription (G1 and G2/M) [40, 41]
ANRIL DNA damage Suppression of p15/p16 transcription with PRC1/2 (G1) [31, 32, 52]
lncRNA-HEIH High expression In HCC Suppression of p16. p21, p27 and p57 transcription with PRC2(G0/G1) [53]
HULC HBx-mediated Suppression of p18 expression (G1) [60–62]
KCNQ10T1 Paternal expression Suppression of p57 transcription with PRC2 and G9a (G1?} [64]
H19 lncRNA e2F1-mediated Downregulation of RB mRNA via miR675 (G1) [69–71]
lncRNA-RoR p53-mediated Suppression of p53 mRNA translation (G2/M) [74]
p53-induced eRNA p53-mediated Promotion of p53 target genes transcription (G1?) [75]
loc285194 p53-mediated Growth inhibition by suppression of miR211 (G1?) [76]
lncRNA-p21 p53-mediated Suppression of transcription of the target genes involved in apoptosis and 
cell cycle with hnRNA-K (G1?) suppression of β-catenin and Jun B mRNA 
translation
[77, 78]
PANDA DNA damage Suppression of FAS and BIK transcription (G1?) [79]
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cell cycle progression such as the genes encoding cyclin 
A2 and Cdc25A, thereby arresting the cell cycle in G1. 
Moreover, in G2/M progression, MALAT1 is required for 
expression of B-Myb, which is involved in the expression 
of mitotic proteins such as cyclin B1, CDK1, FoxoM1, and 
PLK by controlling the splicing of B-Myb mRNA [39]. 
Therefore, MALAT1 may contribute to cell cycle progres-
sion in each phase by coordinated control of cell cycle 
regulators.
Steroid receptor RNA activator (SRA) was identified 
as an lncRNA that binds to steroid receptors [40]. SRA 
forms the SRC-1 complex to activate transcription, medi-
ated by steroid receptors such as progesterone receptor and 
estrogen receptor. It also binds to various other proteins 
such as myoD, and has multiple cellular functions such 
as myogenesis. SRA also binds to PPARγ and coactivates 
gene expression mediated by PPARγ. As such, SRA regu-
lates adipogenesis and insulin sensitivity via PPARγ [41]. 
Additionally, SRA shows PPARγ-independent activity. 
Overexpression of SRA in pre-adipocytes downregulates 
the expression of cell cycle-promoting genes such as those 
encoding the cyclins [cyclins (A2, B1/2)], CDC20, MCMs 
(3, 4, 5, 6), and CDT1. Conversely, these genes are upreg-
ulated by depletion of SRA. However, it remains to be 
elucidated whether SRA directly or indirectly suppresses 
the transcription of these genes, and further investigation 
into the mechanisms of SRA-regulated gene expression is 
required.
LncRNAs regulating CDK inhibitors
INK4 family inhibitors
The CDK inhibitory proteins, p16ink4a and p15ink4b (hereaf-
ter p16 and p15), bind to and inhibit CDK4 and 6, respec-
tively, via their ankyrin repeats [3, 42]. The p15 and p16 
genes (CDKN2B and CDKN2A, respectively) are located 
at the INK4 locus together with the alternating reading 
frame gene, ARF [42]. ARF inhibits MDM2-dependent 
degradation of both p53 [43] and pRB [44]. Therefore, the 
expression of INK4 locus genes is critical for cell cycle 
regulation. The INK4 proteins are relatively stable, and 
their ubiquitin-dependent proteolysis is not particularly 
important for controlling their cellular levels. Therefore, 
the INK4 locus genes are mainly regulated by transcrip-
tion. The participation of several transcription factors, 
including the eTS family [45], FOXO [46], and SP1 [47], 
has been reported. Moreover, the locus is regulated epige-




















Fig. 2  Model showing the proposed mechanisms of lncRNA-medi-
ated regulation of cyclin D1 (a) and CDK6 (b) induced by DNA 
damage. a DNA damage induces the transcription of ncRNACCND1 
from the promoter region of the cyclin D1 gene. ncRNACCND1 asso-
ciates with and recruits TLS, an RNA binding protein, to the cyclin 
D1 promoter. The ncRNACCND1–TLS complex inhibits the CBP/
p300–pCAF–CReB coactivator complex and thereby prevents cyclin 
D1 gene transcription. b DNA damage induces the expression of the 
lncRNA, gadd7, which dissociates TDP-43 from the CDK6 mRNA 
to destabilize it, and CDK6 is thereby downregulated, inhibiting the 
G1/S transition. The lncRNAs gadd7 and ncRNACCND1 may collabo-
ratively participate in the G1 checkpoint in response to DNA damage
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DNA methyltransferase and is involved in the INK4 locus 
via methylation of CpG islands [48]. Moreover, PcG is 
recruited to the INK4 locus, thereby suppressing transcrip-
tion via histone H3K27 methylation [49].
It has been suggested that antisense RNA transcribed 
near the p15 gene controls transcription of p15 [50]. Pas-
mant et al. identified an lncRNA, ANRIL, as an anti-sense 
transcript of the p15 gene in the INK4 locus [51]. Both 
our study and other research have revealed that ANRIL is 
involved in epigenetic repression of the transcription of 
the INK4 locus [31, 32] (Table 1). we found that depletion 
of ANRIL by short hairpin RNA (shRNA) decreased the 
recruitment of SUZ12 to the INK4 locus and promoted the 
expression of p15 gene dramatically and p16 gene mod-
erately, but had no effect on ARF [31]. SUZ12 is a com-
ponent of the PRC2 complex. In contrast, Yap et al. [32] 
demonstrated that ANRIL binds to CBX7, a component of 
the PRC1 complex, in the chromatin fraction, and recruits 
PRC1 to the INK4 locus to mediate transcriptional sup-
pression. Therefore, ANRIL binds to the PRC2 complex 
to recruit it to the INK4 locus, and then histone H3K27 
methylation is mediated by eZH2 in the PRC2 complex. 
Next, PRC2 with ANRIL is recognized by CBX7, and the 
PRC1 complex is recruited to the region. Further, his-
tone H2AK119 monoubiquitination is induced to repress 
transcription of the INK4 locus. Moreover, we demon-
strated that depletion of ANRIL promotes growth arrest 
and induces senescence-associated beta-galactosidase 
in wI38 human fibroblasts [31]. Yap et al. [32] also sug-
gested that CBX7-mediated suppression of the INK4 locus 
is involved in regulating cellular senescence. These reports 
strongly suggest that ANRIL participates not only in cell 
proliferation but also in suppressing premature senescence 
via the recruitment of PRC1 and PRC2 to the INK4 locus 
(Fig. 3a).
It is important to understand how ANRIL expression is 
regulated. we found that excess RAS signaling promoted 
by the introduction of activated H-RasG12v into wI38 
fibroblasts suppressed ANRIL expression and induced 
p15 and p16, thereby arresting the cell cycle and inducing 
senescence-associated beta-galactosidase [31] (Fig. 3b). 
Recently, wan et al. [52] reported that ANRIL is induced 
by DNA-damaging agents via the ATM-e2F1 pathway, but 
p53 is not induced. Moreover, they suggested that depletion 
of ANRIL decreases homologous recombination after DNA 
double-strand breaks, although it is unclear whether ANRIL 
promotes DNA repair via the recruitment of PRC1 and 
PRC2 to the INK4 locus. Further studies are required on 
ANRIL function in response to cellular stresses. Moreover, 
Yang et al. found that lncRNA-HEIH is highly expressed in 
HBv-related hepatocellular carcinoma. It negatively regu-
lates the expression of CDK inhibitors, such as p15, p16, 
p21, and p57, via interacting with eZH2, and then plays an 
important role in G0/G1 arrest [53] (Table 1).
p18ink4c (hereafter p18) is another INK4 family CDK 
inhibitor that also inhibits both CDK4 and 6 [3, 54]. 
Recently, ink4c−/− mice have been shown to develop 
spontaneous pituitary adenomas [55], the frequency of 
which is enhanced by deletion of other CDK inhibi-
tor genes [56]. The combined deletion of the p18 gene 
(CDKN2C) with the p16 gene is also found in human can-
cers [57]. Moreover, the expression levels of p16 and p18 
are often inversely correlated during the progression of 
senescence [58]. It has been reported that transcription of 
the p18 gene is regulated by Menin-ReT-signaling and the 
































Fig. 3  Model showing the proposed mechanisms of ANRIL-mediated 
regulation of the INK4 locus. a Model of ANRIL-mediated repression 
of the INK4 locus. ANRIL binds to the PRC2 complex to recruit it to 
the INK4 locus. Then, histone H3K27 methylation (M) is mediated 
by eZH2 in the PRC2 complex with ANRIL, which is recognized by 
CBX7 to recruit the PRC1 complex to the region. Histone H2AK119 
monoubiquitination (Ub) is thereby induced to repress the transcrip-
tion of INK4. b excess RAS signaling suppresses the expression of 
ANRIL. Overexpression of activated H-RasG12v in wI38 fibroblasts 
promotes excess RAS signaling and suppresses ANRIL expression. 
Then, p15 and p16 are induced and the cell cycle undergoes arrest, 
inducing a premature senescence-like phenotype
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lncRNA, HULC, negatively regulates the expression of p18 
gene, which is located near the region containing HULC 
(Table 1). HULC was identified as an lncRNA upregulated 
in human hepatocellular carcinoma (HCC) [61] that is tran-
scribed in a CReB-dependent manner [62]. Moreover, the 
expression of p18 is induced and suppressed by depletion 
and overexpression of HULC, respectively. The expression 
of p18 is inversely correlated with the expression of HULC 
in human HCC tissue specimens. Furthermore, the hepa-
titis B virus oncogene product, HBx, activates the HULC 
promoter via CReB to suppress the transcription of the 
p18 gene by upregulated HULC [60]. Downregulation of 
the p18 gene by HBx via HULC induction may contribute 
to the development of HCC, although it is unknown how 
HULC suppresses the transcription of the p18 gene.
Cip/Kip family inhibitors
The transcription of p57Kip2 gene (CDKN1C), which is 
located at the KCNQ1 domain, is epigenetically suppressed 
as an imprinted gene on the paternal chromosome [63]. 
KCNQ1OT1 is paternally expressed as an antisense RNA 
of the KCNQ1 domain containing KCNQ1 and the p57Kip2 
gene [64]. KCNQ1OT1 functions as a recruiter that asso-
ciates with the chromatin modifiers, PRC2 and G9a, and 
recruits them to the KCNQ1 domain to suppress the tran-
scription of p57Kip2 gene (Table 1). As described above, 
lncRNA-HEIH downregulates the expression of not only 
the INK4 family inhibitors, p15 and p16, but also the Cip/
Kip family inhibitors, p21 and p57 [53].
LncRNAs regulating the pRB pathway
As described above, the tumor suppressor pRB is a critical 
regulator of G1/S progression [7, 65]. It is well known that 
the expression of the RB gene is epigenetically silenced by 
methylation of the promoter in some cancers, including ret-
inoblastoma [66]. Hypermethylation of the CTCF binding 
site in the RB promoter is mediated by the CTCF protein 
[67]. CTCF also regulates the expression balance between 
the IGF2/H19 locus together with DNA methylation of their 
promoters as an insulator of gene expression [68]. Interest-
ingly, the H19 gene encodes a 2.9-kb lncRNA, and the H19 
lncRNA is a precursor of miR-675 [69]. The expression of 
H19 lncRNA is mediated by e2F1 and promotes cell pro-
liferation [70], but the mechanism is unknown. Tsang et al. 
[71] reported that the H19 lncRNA-derived miR-675 asso-
ciates with the 3′ untranslated region of RB mRNA to nega-
tively regulate pRB expression (Fig. 4; Table 1). In human 
colorectal cancer, H19 lncRNA/miR-675 expression is 
inversely correlated with pRB expression [71]. Therefore, 
H19 lncRNA/miR-675 may be a critical negative regulator 





























Fig. 4  Model showing the proposed mechanisms of lncRNA-medi-
ated regulation of the RB pathway. pRB binds target transcription fac-
tors such as e2F and inhibits their activity in the G1 phase. Cyclin 
Ds-CDK4/6 phosphorylate pRB and activate e2F-mediated transcrip-
tion in late G1, which regulates the expression of several growth-pro-
moting genes and S phase entry. The transcription of H19 lncRNA 
from the H19 locus is mediated by e2F1. H19 lncRNA is processed to 
generate miR-675, which binds to RB mRNA and inhibits its transla-
tion
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pRB suppresses e2F-dependent transcription of H19 tran-
scription via repression of the H19 promoter. Therefore, the 
H19-RB axis is self-regulated.
LncRNAs regulating the p53 pathway
Another important tumor suppressor, p53, functions as the 
gatekeeper of the genome to control cell cycle arrest and 
apoptosis in response to DNA damage [65, 72]. Although 
p53 is unstable, it is stabilized and activated via phospho-
rylation mediated by the ATM/ATR pathway in response 
to DNA damage. Moreover, p53 is also regulated via phos-
phorylation at various sites by specific kinases [73]. Zang 
et al. [74] reported that lncRNA-RoR negatively regulates 
p53 expression, thereby suppressing doxorubicin-induced 
G2/M arrest and apoptosis (Table 1). Depletion of lncRNA-
RoR leads to p53 accumulation, and overexpression of 
lncRNA-RoR suppresses p53 expression. LncRNA-RoR 
binds to phosphorylated heterogeneous nuclear ribonucleo-
protein I (p-hnRNP-I) in cytoplasm and thereby suppresses 
p53 translation. The 28-base RoR sequence is sufficient 
for its function. Additionally, wild-type p53 binds to the 
RoR promoter to promote transcription of lncRNA-RoR, 
but mutant p53 does not bind to this promoter. This is a 
novel autoregulatory feedback loop that controls p53 levels 
(Fig. 5).
Recently, Melo et al. [75] reported that enhancer RNAs 
(eRNAs) are required for coordinated promotion between 
p53 target genes and p53-bound enhancer regions distant 
from the target gene, and participate in p53-dependent 
cell cycle arrest (Table 1). LncRNA loc285194 was sug-
gested to have a tumor suppressor function, but its mech-
anism was unknown. Liu et al. found that loc285194 is 
induced by binding of p53 to its binding site in the pro-
moter (Table 1). Moreover, they indicated that loc285194 
binds to and inhibits miR-211, thereby downregulating 
miR-211-mediated cell proliferation [76]. Loc285194 is 
downregulated in human colon cancer specimens, and thus 
may contribute to the tumor suppressive function of p53 to 
inhibit miR-211 [76].
Huarte et al. [77] identified lncRNA-p21, which is tran-
scribed near the p21Cip1 gene (CDKN1A) as a p53-tar-
get gene. p53 directly binds to its binding element in the 
































Fig. 5  Model showing the proposed mechanisms of lncRNA-medi-
ated regulation of the p53 pathway. p53 controls cell cycle arrest, 
repair, and apoptosis in response to DNA damage. lncRNA-RoR binds 
to hnRNP-I and collaboratively suppresses p53 mRNA translation. 
This is an autoregulatory feedback loop that controls p53 levels. In 
response to DNA damage, p53 is stabilized and activated via phos-
phorylation mediated by the ATM/ATR pathway. p53 directly binds 
the target genes and regulates their expression to control cell cycle 
arrest, repair, and apoptosis. eRNAs are involved in promotion of 
p53-target genes in p53-dependent cell cycle arrest. p21 and lncRNA-
p21, which is transcribed near the p21Cip1 gene, are p53-target genes. 
lncRNA-p21 controls the expression of some p53-target genes. p53 
function is partially mediated by gene regulation via lncRNA-p21
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the expression of some p53-target genes except for p21 
gene and inhibits apoptosis (Fig. 5; Table 1). lncRNA-
p21 binds to hnRNP-K and recruits it to the target genes, 
but the mechanism of target gene regulation is unknown. 
p53 function is partially mediated by gene regulation via 
lncRNA-p21-hnRNP-K. Moreover, Yoon et al. proposed 
that lncRNA-p21 functions as a modulator of transla-
tion. lncRNA-p21 associates with target mRNAs such as 
β-catenin and JunB in collaboration with Rck/p54 RNA 
helicase, and thus the translation of the target mRNAs is 
repressed [78]. Therefore, lncRNA-p21 regulates both tran-
scription in the nucleus and translation in the cytoplasm.
PANDA (p21-associated ncRNA DNA damage-acti-
vated) was identified as a p21 promoter-derived transcript 
using ultra-high density tiling array of 56 cell-cycle genes. 
It is induced by DNA damage in a p53-dependent man-
ner [79] (Table 1). PANDA binds to and inhibits NF-YA 
transcription factor, which limits the expression of proa-
poptotic genes such as FAS and BIK and results in the 
repression of apoptosis. PANDA is selectively induced in 
metastatic ductal carcinomas but not in normal breast tis-
sue [79]. The results suggest that abnormal overexpression 
of PANDA may suppress apoptosis induced by DNA dam-
age, which will accumulate and push the genome toward 
carcinogenesis.
Perspectives
Although the mechanisms of cell cycle regulation via 
cyclin–CDK, the p53/RB pathway, and the checkpoint 
pathway have been described in detail, recent studies on 
lncRNAs strongly suggest that lncRNAs control the expres-
sion of cell cycle regulators. Therefore, lncRNAs are 
critically involved in cell cycle regulation. However, it is 
unclear why lncRNAs might be deployed to regulate the 
cell cycle. As described in the “Introduction”, lncRNAs 
involved in cell cycle regulation are classified into four 
groups. As shown in Table 1, ANRIL, lncRNA-HEIH, and 
KCNQ1OT1 are involved in epigenetic regulation of target 
gene transcription by collaborating with chromatin modi-
fiers, which are classified as epigenetic regulators. ncR-
NACCND1, SRA, PANDA, and lncRNA-p21 directly interact 
with the transcriptional machinery on the target genes and 
collaboratively regulate transcription as transcription factor 
regulators. Post-transcription regulators including gadd7, 
MALAT1, lncRNA-RoR, and loc285194 bind to their spe-
cific target mRNA to suppress translation and/or to mod-
ulate mRNA stability. SRA and MALAT1 also promote 
protein–protein interactions and are classified as protein 
scaffolds. Because the general cell cycle is closely associ-
ated with various cellular events as well as biological pro-
cesses, it should be accurately regulated. Post-transcription 
regulators such as gadd7, MALAT1, H19 lncRNA, and 
loc285194 can rapidly and transiently suppress translation 
of their target genes. Transcription factor regulators such as 
ncRNACCND1, SRA, PANDA, and lncRNA-p21 that directly 
interact with the transcription machinery on the target 
genes may also participate in transient regulation. Alterna-
tively, epigenetic regulators such as ANRIL, lncRNA-HEIH, 
and KCNQ1OT1 may have long-term effects on cellular 
senescence and imprinting because they mediate epige-
netic regulation of cell cycle regulatory genes via chroma-
tin modifiers. From this viewpoint, the cell cycle-regulated 
lncRNAs mainly control cellular levels of cell cycle regu-
lators via various mechanisms, and may provide diversity 
and reliability to the general cell cycle.
It is interesting that many lncRNAs are associated with 
the DNA damage response. As shown in Table 1, 4 of 14 
lncRNAs, lncRNACCND1, gadd7, ANRIL and PANDA, are 
induced by DNA damage. Another 4 lncRNAs, lncRNA-
RoR, lncRNAp21, p53-induced eRNA, and loc285194, are 
induced in a p53-dependent manner, suggesting that they 
are induced by DNA damage. Therefore, these reported 
lncRNAs may participate in cell cycle arrest or induction 
of apoptosis as non-canonical DNA damage responses, 
whereas the ATM/ATR pathway is involved in a canoni-
cal DNA damage response to inactivate CDK activity as a 
DNA damage checkpoint. LncRNAs-mediated non-canon-
ical pathways may ensure the response to DNA damage is 
diverse and reliable depending on the cellular context.
Considering the recent progress in lncRNA research, 
many lncRNAs that have a functional role in cell cycle 
regulation remain to be identified because the functions of 
only a small percentage of the total lncRNA population are 
understood. To clarify the roles of lncRNAs in cell cycle 
regulation, it should be determined how they regulate the 
target cell cycle regulators and which signaling pathways 
induce these lncRNAs. Since abrogation of the cell cycle 
is closely associated with cancer development and growth, 
cell cycle regulatory lncRNAs such as ANRIL and PANDA 
may have oncogenic properties. The importance of lncR-
NAs in cell cycle regulation will be clarified by further 
pathological studies. Moreover, these cell cycle regulatory 
lncRNAs may be novel candidate molecular targets for can-
cer therapy or diagnosis.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribu-
tion, and reproduction in any medium, provided the original author(s) 
and the source are credited.
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